Results from prospective multicentre study with 5-7 years’ follow-up of the first Swedish Episealer® Knee patients accepted for publication
Episurf Medical (Nasdaq: EPIS B) today announces that results from a multicentre study with 5-7 years’ follow-up of Episealer® patients have been accepted for publication in the scientific journal Archives of Orthopaedic and Trauma Surgery. The publication with the title “Good subjective outcome and low risk of revision surgery with a novel customized metal implant for focal femoral chondral lesions at a follow-up after a minimum of five years” is based on the results from a prospective, consecutive cohort study with the objective to assess subjective and objective outcome at a minimum of five years after implantation of an Episealer® Knee implant. The publication is expected to be available online shortly.
The Episealer® Knee implant is intended for treatment of focal cartilage and underlying bone defects on the femoral side of the knee joint. These defects often imply severe pain, which significantly can impact the patient’s quality of life. Current standard of care, which includes various biological treatment alternatives, has shown limited effectiveness, especially with increasing age.
The study with Ass. Prof. A. Stålman at Capio Artro Clinic in Stockholm as principal investigator was initiated in 2012 and has focused on the clinical outcome for the 10 very first Swedish Episealer® Knee patients. The 2 years’ result from this study was published by A. Stålman et al. in the scientific journal Knee Surgery, Sports Traumatology, Arthroscopy in 2018.
“This publication is unique for the orthopaedic segment we are operating in, not only because of the strong results we have been informed about, but also because of the relatively long follow-up of the patients and for the fact that there are no implant revisions within this group at up to 7 years’ follow-up. We have now over the last 12 months seen a number of publications with positive clinical results of Episealer® patients. This is the first publication on the Episealer® from a prospective cohort study with a minimum of 5 years’ clinical follow-up, and this is a significant milestone for us. These results will add to an already strong clinical foundation, and the results will be of great value to us in our discussions with potential customers, payors and patients in this industry”, says Pål Ryfors, CEO Episurf Medical.
This disclosure contains information that Episurf is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-09-2021 08:00 CET.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.